Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement (Quercetin)
Hypoxia-inducible Transcription Factor 1 (HIF-1) in Vascular Aging
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy volunteers between the ages of 18-75 years old
Exclusion Criteria:
- subjects taking vasoactive medications
- hypertension or vascular disease
- asthma
- smokers
- pregnant women
- cancer
- diabetes mellitus
- history of seizures
- history of stroke or head trauma
- subjects taking digoxin, cyclosporine,felodipine, estradiol, or quinolone antibiotics
- poor transcranial Doppler insonation windows
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: healthy young
|
Quercetin 500mg once per day versus placebo
|
|
Experimental: healthy old
|
Quercetin 500mg once per day versus placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Define change from baseline levels of HIF-1 concentration and 3 of its regulated proteins after 6 months of quercetin (versus placebo) dietary intake.
Time Frame: 6 months
|
Baseline and 6 month blood samples will be analyzed for levels of HIF-1, VEGF, EPO, and NOS
|
6 months
|
|
Determine change from baseline brain blood flow after 6 months of quercetin (versus placebo) dietary intake.
Time Frame: 6 months
|
Determine cerebral vasomotor reactivity response to 6 months of quercetin intake by measuring changes in middle cerebral artery (MCA) blood flow velocity in response to changes in end-tidal CO2, and assess neurovascular coupling by measuring changes in MCA flow velocity in response to neuropsychological tasks.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Define change from baseline performance in a battery of cognitive tasks after 6 months of quercetin (versus placebo) dietary intake.
Time Frame: 6 months
|
Assess effects of 6 months of quercetin intake on cognitive function using a cognitive battery designed to asses both memory and executive function.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Farzaneh Sorond, mD, PhD, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1 K23AG030967-01A1-2
- 1K23AG030967-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.